DexCom Inc DXCM shares are trading higher in Thursday's after-hours session after the company reported better-than-expected financial results.
DexCom said third-quarter revenue increased 18% year-over-year to $769.6 million, which beat average analyst estimates of $751.71 million, according to Benzinga Pro. U.S. revenue jumped 17% year-over-year, while international revenue increased 22%.
DexCom reported quarterly earnings of 28 cents per share, which beat average estimates of 24 cents per share. The company said it ended the quarter with $2.37 billion in cash and equivalents.
"With the international roll-out of G7, strong momentum in our US business, and ongoing efforts to broaden global access, we are well positioned for a strong conclusion to the year," said Kevin Sayer, chairman, president, and CEO of DexCom.
DexCom expects full-year revenue to be between $2.88 billion and $2.91 billion versus average analyst estimates of $2.89 billion.
DexCom empowers people to take control of diabetes through innovative continuous glucose monitoring systems.
See Also: Why Gilead Sciences Stock Is Rising After Hours
DXCM Price Action: DexCom has a 52-week high of $164.86 and a 52-week low of $66.89.
The stock was up 8.69% in after-hours at $110.05 at the time of publication.
Photo: Lorenzo Cafaro from Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.